BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22724917)

  • 21. Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly.
    Kuendgen A; Germing U
    Cancer Treat Rev; 2009 Apr; 35(2):97-120. PubMed ID: 18951721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?
    Feldman EJ
    Best Pract Res Clin Haematol; 2011 Dec; 24(4):523-6. PubMed ID: 22127315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel strategies for relapsed and refractory acute myeloid leukemia.
    Mato AR; Morgans A; Luger SM
    Curr Opin Hematol; 2008 Mar; 15(2):108-14. PubMed ID: 18300756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape.
    Sedov V; Stuart RK
    Ther Adv Hematol; 2017 Jun; 8(6):185-195. PubMed ID: 28567238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia.
    List AF
    Leukemia; 1996 Apr; 10 Suppl 1():S36-8. PubMed ID: 8618469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amonafide: a potential role in treating acute myeloid leukemia.
    Allen SL; Lundberg AS
    Expert Opin Investig Drugs; 2011 Jul; 20(7):995-1003. PubMed ID: 21591994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
    Prebet T; Vey N
    Expert Opin Investig Drugs; 2011 Feb; 20(2):287-95. PubMed ID: 21192773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of decitabine for the treatment of acute myeloid leukemia.
    Ganetsky A
    Ann Pharmacother; 2012 Nov; 46(11):1511-7. PubMed ID: 23115225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?
    Freeman CL; Swords R; Giles FJ
    Expert Rev Hematol; 2012 Feb; 5(1):17-26. PubMed ID: 22272701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigational drugs targeting FLT3 for leukemia.
    Ustun C; DeRemer DL; Jillella AP; Bhalla KN
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1445-56. PubMed ID: 19671038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults.
    Tran H; Yang D
    Ann Pharmacother; 2012 Jan; 46(1):89-96. PubMed ID: 22170975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
    Willman CL
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):25-33. PubMed ID: 9408958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
    Creutzig U; Büchner T; Sauerland MC; Zimmermann M; Reinhardt D; Döhner H; Schlenk RF
    Cancer; 2008 Feb; 112(3):562-71. PubMed ID: 18076087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
    Braun T; Fenaux P
    Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical development of FLT3 inhibitors in acute myeloid leukemia.
    Knapper S
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1377-95. PubMed ID: 21895538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and conduct of a double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: a Southwest Oncology Group study.
    Godwin J
    J Natl Cancer Inst Monogr; 1995; (19):31-5. PubMed ID: 7577202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel and emerging drugs for acute myeloid leukemia.
    Stein EM; Tallman MS
    Curr Cancer Drug Targets; 2012 Jun; 12(5):522-30. PubMed ID: 22483153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients.
    van der Holt B; Van den Heuvel-Eibrink MM; Van Schaik RH; van der Heiden IP; Wiemer EA; Vossebeld PJ; Löwenberg B; Sonneveld P
    Clin Pharmacol Ther; 2006 Nov; 80(5):427-39. PubMed ID: 17112800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia.
    Ferrara F; Palmieri S; Mele G
    Haematologica; 2004 Aug; 89(8):998-1008. PubMed ID: 15339685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.